Mixed ligand gold(III) complexes and methods thereof

Patent metadata

Field	Value
Publication number	US-9487542-B1
Application number	US-201514798071-A
Country	US
Kind code	B1
Filing date	Jul 13, 2015
Priority date	Jul 13, 2015
Publication date	Nov 8, 2016
Grant date	Nov 8, 2016

Abstract

Gold(III) complexes having mixed ligands as anticancer agents. The atom is coordinated by bidentate ligands having diamino functional groups: a diaminocyclohexane ligand and an ethylenediamine ligand. These complexes can exist in both cis- and trans-configurations. Also described are pharmaceutical compositions incorporating the gold(III) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer cell proliferation and inducing cancer cell apoptosis.

First claim

The invention claimed is:

1. A gold(III) complex having Formula A:

or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof;
wherein:
the complex has a cis- or trans-configuration;
1-6 each represents a carbon atom;
R 1 -R 8 are each independently selected from the group consisting of a hydrogen atom; a linear or branched, substituted or unsubstituted C 1 -C 8 alkyl group; and a substituted or unsubstituted C 6 -C 8 aryl group; and
R 9 -R 20 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group a N-monosubstituted amino group, a N,N-disubstituted amino group, a substituted or unsubstituted C 1 -C 8 alkyl group, a substituted or unsubstituted C 1 -C 8 alkoxy group a substituted or unsubstituted C 3 -C 8 cycloalkyl group, and a substituted or unsubstituted C 6 -C 8 aryl group.

2. The gold(III) complex of claim 1 , wherein:
R 1 -R 8 are each independently selected from the group consisting of a hydrogen atom, a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted propyl group, a substituted or unsubstituted isopropyl group, a substituted or unsubstituted n-butyl group, a substituted or unsubstituted isobutyl group, a substituted or unsubstituted sec-butyl group, a substituted or unsubstituted tert-butyl group, a substituted or unsubstituted n-pentyl group, a substituted or unsubstituted neopentyl group, a substituted or unsubstituted sec-pentyl group, a substituted or unsubstituted tert-pentyl group, a substituted or unsubstituted n-hexane group, a substituted or unsubstituted isohexane group, and a substituted or unsubstituted neohexane group; and
R 9 -R 20 are each independently a hydrogen atom, a halogen atom, a N-monosubstituted amino group, a N,N-disubstituted amino group, a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted propyl group, a substituted or unsubstituted isopropyl group, a substituted or unsubstituted n-butyl group, a substituted or unsubstituted isobutyl group, a substituted or unsubstituted sec-butyl group, a substituted or unsubstituted tert-butyl group, a substituted or unsubstituted n-pentyl group, a substituted or unsubstituted neopentyl group, a substituted or unsubstituted sec-pentyl group, a substituted or unsubstituted tert-pentyl group, a substituted or unsubstituted n-hexane group, a substituted or unsubstituted isohexane group, and a substituted or unsubstituted neohexane group.

3. The gold(III) complex of claim 1 , having a formula selected from the group consisting of Formula 1a, Formula 1b, Formula 2a and Formula 2b:

4. The gold(III) complex of claim 1 , further comprising one or more pharmaceutically acceptable anions selected from the group consisting of fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, amide, methanesulfonate, ethanesulfonate, p-toluenesulfonate, salicylate, malate, maleate, succinate, tartarate, citrate, acetate, perchlorate, trifluoromethanesulfonate, acetylacetonate, hexafluorophosphate, and hexafluoroacetylacetonate.

5. A composition, comprising:
the gold(III) complex of claim 1 or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof; and
one or more pharmaceutically acceptable carriers.

6. The composition of claim 5 , further comprising one or more other active pharmaceutical agents.

7. The composition of claim 5 , wherein the composition is in solid, semi-solid or liquid dosage forms.

8. The composition of claim 5 , wherein the composition is formulated for one or more modes of administration selected from the group consisting of oral administration, systemic administration, parenteral administration, inhalation spray, infusion, rectal administration, topical administration, intravesical administration, intradermal administration, transdermal administration, subcutaneous administration, intramuscular administration, intralesional administration, intracranial administration, intrapulmonal administration, intracardial administration, intrasternal administration and sublingual administration.

9. A method for treating one or more types of cancer in a mammalian subject in need thereof, comprising:
administering a therapeutically effective amount of the composition of claim 5 to the mammalian subject; wherein the one or more types of cancer are prostate cancer and/or gastrointestinal cancer.

10. The method of claim 9 , wherein the therapeutically effective amount comprises 5-50 μM of the gold(III) complex or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof.

11. A method for inhibiting proliferation of cancer cells, comprising:
contacting the cancer cells with the gold(III) complex of claim 1 or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof; wherein the cancer cells are prostate cancer cells and/or gastrointestinal cancer cells.

12. The method of claim 11 , wherein the cancer cells are human cells.

13. The method of claim 11 , wherein the gold(III) complex has a concentration of 5-50 μM.

14. The method of claim 11 , wherein the gold(III) complex exhibits an IC 50 of 1-20 μM for inhibiting the proliferation of the prostate cancer cells and/or the gastrointestinal cancer cells.

Assignees

• Univ King Fahd Pet & Minerals

Inventors

• Al-Jaroudi Said
• Altaf Muhammad
• Al-Saadi Abdulaziz
• Isab Anvarhusein Abdulkadir

Classifications

• C07F1/005 Primary

  without C-Metal linkages · CPC title

• A61K31/28 Primary

  Compounds containing heavy metals · CPC title

• C07F1/12 Primary

  Gold compounds · CPC title